FGF21/adiponectin ratio predicts deterioration in glycemia: a 4.6-year prospective study in China

Abstract Background The fibroblast growth factor (FGF) 21-adiponectin pathway is involved in the regulation of insulin resistance. However, the relationship between the FGF21-adiponectin pathway and type 2 diabetes in humans is unclear. Here, we investigated the association of FGF21/adiponectin ratio with deterioration in glycemia in a prospective cohort study. Methods We studied 6361 subjects recruited from the prospective Shanghai Nicheng Cohort Study in China. The association between baseline FGF21/adiponectin ratio and new-onset diabetes and incident prediabetes was evaluated using multiple logistic regression analysis. Results At baseline, FGF21/adiponectin ratio levels increased progressively with the deterioration in glycemic control from normal glucose tolerance to prediabetes and diabetes (p for trend < 0.001). Over a median follow-up of 4.6 years, 195 subjects developed new-onset diabetes and 351 subjects developed incident prediabetes. Elevated baseline FGF21/adiponectin ratio was a significant predictor of new-onset diabetes independent of traditional risk factors, especially in subjects with prediabetes (odds ratio, 1.367; p = 0.001). Moreover, FGF21/adiponectin ratio predicted incident prediabetes (odds ratio, 1.185; p = 0.021) while neither FGF21 nor adiponectin were independent predictors of incident prediabetes (both p > 0.05). Furthermore, net reclassification improvement and integrated discrimination improvement analyses showed that FGF21/adiponectin ratio provided a better performance in diabetes risk prediction than the use of FGF21 or adiponectin alone. Conclusions FGF21/adiponectin ratio independently predicted the onset of prediabetes and diabetes, with the potential to be a useful biomarker of deterioration in glycemia.

Download Full-text

Cardiorespiratory fitness in the population with different glucose metabolic statuses: low cardiorespiratory fitness increases the risk of early abnormal glucose metabolism

10.21203/rs.3.rs-126246/v1 ◽

2020 ◽

Author(s):

Rui Wang ◽

Xiaoli Liu ◽

Lanxiang Liu ◽

Xiaojiao Jia ◽

Qiang Lu

Keyword(s):

Risk Factor ◽

Blood Glucose ◽

Glucose Metabolism ◽

Cardiorespiratory Fitness ◽

Normal Glucose Tolerance ◽

Abnormal Glucose Metabolism ◽

Onset Diabetes ◽

Normal Glucose ◽

New Onset

Abstract Background: Low cardiorespiratory fitness (CRF) is a risk factor for many chronic diseases. This study aims to evaluate CRF in the population with different glucose metabolism and explore its relationship with early abnormal glucose metabolism.Method: A total of 93 participants were assigned to three groups: normal glucose tolerance (NGT); impaired glucose regulation (IGR); and newly diagnosed type 2 diabetes mellitus (T2DM) through OGTT. CPET was performed to evaluate CRF.Results and Conclusion: The anaerobic threshold (AT), oxygen uptake (VO2) and maximum VO2/kg in male participants, and the AT heart rate (HR), AT systolic blood pressure (Psys) and the maximum VO2/kg in female participants, were lower in the T2DM and IGR groups than in the NGT group. Regression analysis shows that the maximum VO2/kg and 1-min HR recovery of female 2-h blood glucose entered into the equation, the maximum VO2 of male participants was related to pre-diabetes and AT power was related to new-onset diabetes, the AT Psys of female participants was related to pre-diabetes and AT HR was related to new-onset diabetes. CRF was closely associated with 2-h blood glucose after glucose load and was an important risk factor for pre-diabetes and new-onset diabetes.

Download Full-text

A multicenter prospective hospital-based cohort study on the efficacy and safety of pitavastatin.

Current Diabetes Reviews ◽

10.2174/1573399817666201228164243 ◽

2020 ◽

Vol 17 ◽

Author(s):

Abdullah Shehab ◽

Asim Ahmed Elnour ◽

Akshaya Srikanth Bhagavathula ◽

Joseph Pulavelil Kurian ◽

Gazi Hassan ◽

...

Keyword(s):

Cohort Study ◽

Adverse Events ◽

United Arab Emirates ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Low Density ◽

Efficacy And Safety ◽

Onset Diabetes ◽

The Mean ◽

New Onset

Aims: We aim to investigate the efficacy and safety of pitavastatin 4 mg in a population of people living in the United Arab Emirates (UAE). Background: Pitavastatin is a member of the HMG-CoA reductase inhibitors family which was approved for use in adult subjects with primary hyperlipidemia or mixed dyslipidemia. To date, no published studies have assessed the efficacy and safety of pitavastatin in the United Arab Emirates. Objective: The main objective of the current study was to investigate the efficacy and safety of pitavastatin in subjects with dyslipidemia for primary prevention of cardiovascular diseases based on total cardiovascular risk. Methods: This was a multicentre (four private hospitals) prospective cohort study to analyze data on the use of pitavastatin for dyslipidemia in adult outpatients in Abu Dhabi and Dubai emirates, United Arab Emirates. We have followed-up the clinical profiles of subjects in four hospitals for six-weeks during the period from June 2015 to June 2017. Efficacy was based on the evaluation of the mean (± standard deviation) change in low-density lipoprotein cholesterol between baseline and week six after the initiation of pitavastatin therapy. Safety was reported as the incidence of adverse events occurred with the use of pitavastatin and the development of new-onset diabetes. Results: A total of 400 subjects who were receiving pitavastatin 4 mg were included. The mean age of subjects was 50.7 ±10.8 years, of these 79.0% were males. At the baseline, the mean level of total cholesterol was 185.4 ±41.5 mg/dL, low density lipoprotein was 154.9 ±48.55 mg/dL, high-density lipoprotein cholesterol was 40.5 ±11.23 mg/dL and fasting blood glucose was 115.0 (±16.63) mg/dl. At the end of six weeks, low density lipoprotein levels significantly decreased to 112.09 ±41.90 mg/dl (standard mean difference [SMD] (-42.8%), 95% CI: -42.88 [-49.17 to -36.58] mg/dl, P <0.001), while high density lipoprotein levels improved (SMD, 95% CI: 1.77% [0.25 to 3.28] mg/dl, P <0.022). There were 55 subjects (13.7%) reported various adverse events such as myalgia (7.5%), sleep disorders (2.5%), and myopathy (2.2%). Furthermore, 4 (1.0%) have had developed new-onset diabetes post six-weeks of initiation of pitavastatin therapy. Conclusion: Pitavastatin 4 mg had howed robust efficacy in reducing LDL-C levels and improving HDL-C levels in subjects with dyslipidemias. The use of pitavastatin was associated with a low discontinuation rate, fewer adverse events, and very limited cases of new-onset diabetes.

Download Full-text

Eosinophil-to-monocyte ratio is a potential biomarker in the prediction of functional outcome among patients with acute ischemic stroke

BMC Neuroscience ◽

10.1186/s12868-021-00610-x ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Shuhong Yu ◽

Yi Luo ◽

Tan Zhang ◽

Chenrong Huang ◽

Yu Fu ◽

...

Keyword(s):

Ischemic Stroke ◽

Acute Ischemic Stroke ◽

Functional Outcome ◽

Odds Ratio ◽

Poor Outcome ◽

Net Reclassification Improvement ◽

Potential Biomarker ◽

The Impact ◽

The Relationship ◽

Integrated Discrimination Improvement

Abstract Background It has been shown that eosinophils are decreased and monocytes are elevated in patients with acute ischemic stroke (AIS), but the impact of eosinophil-to-monocyte ratio (EMR) on clinical outcomes among AIS patients remains unclear. We aimed to determine the relationship between EMR on admission and 3-month poor functional outcome in AIS patients. Methods A total of 521 consecutive patients admitted to our hospital within 24 h after onset of AIS were prospectively enrolled and categorized in terms of quartiles of EMR on admission between August 2016 and September 2018. The endpoint was the poor outcome defined as modified Rankin Scale score of 3 to 6 at month 3 after admission. Results As EMR decreased, the risk of poor outcome increased (p < 0.001). Logistic regression analysis revealed that EMR was independently associated with poor outcome after adjusting potential confounders (odds ratio, 0.09; 95% CI 0.03–0.34; p = 0.0003), which is consistent with the result of EMR (quartile) as a categorical variable (odds ratio, 0.23; 95% CI 0.10–0.52; ptrend < 0.0001). A non-linear relationship was detected between EMR and poor outcome, whose point was 0.28. Subgroup analyses further confirmed these associations. The addition of EMR to conventional risk factors improved the predictive power for poor outcome (net reclassification improvement: 2.61%, p = 0.382; integrated discrimination improvement: 2.41%, p < 0.001). Conclusions EMR on admission was independently correlated with poor outcome in AIS patients, suggesting that EMR may be a potential prognostic biomarker for AIS.

Download Full-text

Association between preoperative lipid profiles and new‐onset diabetes after transplantation in Chinese kidney transplant recipients: A retrospective cohort study

Journal of Clinical Laboratory Analysis ◽

10.1002/jcla.23867 ◽

2021 ◽

Author(s):

Yangli Ye ◽

Jian Gao ◽

Jing Liang ◽

Yinqiu Yang ◽

Chaoyang Lv ◽

...

Keyword(s):

Cohort Study ◽

Kidney Transplant ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Lipid Profiles ◽

Transplant Recipients ◽

Kidney Transplant Recipients ◽

Onset Diabetes ◽

New Onset

Download Full-text

Statin therapy for primary prevention and its effect on new-onset diabetes, mace and all-cause mortality - A real-world population cohort study

Atherosclerosis ◽

10.1016/j.atherosclerosis.2018.06.240 ◽

2018 ◽

Vol 275 ◽

pp. e86-e87

Author(s):

G. Lavie ◽

O. Reges ◽

M. Hoshen ◽

A. Benis ◽

M. Leibowitz ◽

...

Keyword(s):

Cohort Study ◽

Primary Prevention ◽

Statin Therapy ◽

Real World ◽

World Population ◽

Onset Diabetes ◽

Population Cohort ◽

All Cause Mortality ◽

Population Cohort Study ◽

New Onset

Download Full-text

Insulin action and secretion independent of traditional risk factors predict new‐onset type 2 diabetes in Iraqi and Swedish born citizens – The MEDIM cohort study

Diabetes/Metabolism Research and Reviews ◽

10.1002/dmrr.3509 ◽

2021 ◽

Author(s):

Miriam Pikkemaat ◽

Sara Larsson Lönn ◽

Louise Bennet

Keyword(s):

Risk Factors ◽

Type 2 Diabetes ◽

Cohort Study ◽

Insulin Action ◽

Onset Type ◽

Traditional Risk Factors ◽

New Onset

Download Full-text

Delayed neurological improvement is predictive to long-term clinical outcome on endovascular thrombectomy patients

Interventional Neuroradiology ◽

10.1177/15910199211038207 ◽

2021 ◽

pp. 159101992110382

Author(s):

Haodi Cai ◽

Yunfei Han ◽

Wen Sun ◽

Mingming Zha ◽

Xuan Shi ◽

...

Keyword(s):

Functional Outcome ◽

Clinical Outcomes ◽

Odds Ratio ◽

Predictive Ability ◽

Influential Factors ◽

Confidential Interval ◽

Neurological Improvement ◽

Net Reclassification Improvement ◽

Good Functional Outcome ◽

Integrated Discrimination Improvement

Objectives This study aims at exploring the 3-month outcome predicting ability of delayed neurological improvement and the cause of delayed neurological improvement. Materials and methods Early neurological improvement and delayed neurological improvement were calculated to represent the neurological improvements. Good functional outcome was defined as a 90-day modified Rankin Scale score 0–2. We used multivariant logistic regression to explore the influential factors of good functional outcome as well as delayed neurological improvement. We applied net reclassification improvement and integrated discrimination improvement to assess the quantitative improvement of the predictive model. Results Early neurological improvement was observed in 50 (23%) patients and delayed neurological improvement exhibited in 67 (30%) patients. Early neurological improvement and delayed neurological improvement were both independent predictive factors to good functional outcome. In the basic model (adjusted for age, admission glucose level, baseline National Institute of Health Stroke Scale, and complications and number of retrieval attempts), early neurological improvement and delayed neurological improvement statistically improved the predictive ability (early neurological improvement: net reclassification improvement = 0.34, 95% confidence interval, 95% confidential interval (0.06, 0.69); integrated discrimination improvement = 0.05, p < 0.001; delayed neurological improvement: net reclassification improvement = 0.79, 95% confidential interval (0.47, 1.12); integrated discrimination improvement = 0.14, p < 0.001) delayed neurological improvement could predict clinical outcomes more accurately than early neurological improvement (early neurological improvement vs. delayed neurological improvement: integrated discrimination improvement = 0.09, p < 0.001). Moreover, delayed neurological improvement was affected by hypertension (odds ratio = 0.40, 95% CI (0.18, 0.88), p = 0.02), early neurological improvement (odds ratio = 20.10, 95% confidential interval (8.24, 19.02), p < 0.001), number of retrieval attempts (odds ratio = 0.39, 95% confidential interval (0.24, 0.66), p < 0.001), and complication (odds ratio = 0.25, 95% confidential interval (0.12, 0.54), p < 0.001). Conclusions Delayed neurological improvement could predict clinical outcomes more accurately than early neurological improvement. Hypertension, early neurological improvement, numbers of retrieval attempts, and complications were all predicting factors to delayed neurological improvement.

Download Full-text